

POSTER PRESENTATIONS

THURSDAY, OCT. 29
9:45-10:15A

SCREEN

Subgroup Analysis of the Ongoing Phase Ib DAREON-7 Study: Outcomes With First-Line Obrixtamig Plus Standard of Care in Neuroendocrine Carcinomas by Delta-Like Ligand 3 Expression Status	1
DAREON-8: Updated Efficacy and Safety From a Phase I Dose-Escalation/Expansion Trial of First-Line Obrixtamig Plus Chemotherapy and Atezolizumab in Extensive-Stage Small Cell Lung Carcinoma	2
Darolutamide Plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer: ARASEC – United States Prospective, Open-Label Phase 2 Study With an External Control Arm	3
Cognitive Effects of Darolutamide Versus Enzalutamide: Results of ARACOG (AFT-47), a Randomized Clinical Trial From the Alliance for Clinical Trials in Oncology	4
Zidesamtinib Efficacy and Safety in Patients With Advanced ROS1-Positive Solid Tumors Other Than Non-Small Cell Lung Cancer in the ARROS-1 Study	5
Eflapegrastim, a Long-Acting Granulocyte Colony-Stimulating Factor, Administered the Same Day as Chemotherapy in Patients With Early-Stage Breast Cancer: Results From a Multicenter, Open-Label Study	6
First-Line NALIRIFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma and Pre-Existing Diabetes: NAPOLI 3 Post Hoc Analysis	7
Efficacy and Safety of Ivonescimab-Chemotherapy Versus Placebo-Chemotherapy in Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor-Resistant, Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer in the Phase 3 HARMONi Study	8
Intracranial Efficacy of Tarlatamab Versus Chemotherapy as Second-Line Treatment for Small Cell Lung Cancer: DeLLphi-304 Phase 3 Post Hoc Analysis	9
Outpatient Step-Up Dosing and Safety With Talquetamab: A Real-World Mayo Clinic Study	10
Optec/Optal: A Phase 2 Study to Evaluate Outpatient, Step-Up Administration of Teclistamab or Talquetamab With Prophylactic Tocilizumab in Patients With Relapsed/Refractory Multiple Myeloma	11
Management of Chemotherapy-Induced Adverse Events in Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A United States-Based Modified Delphi Consensus	12
Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer: IDEate-Lung01 Updated Results	13
Imetelstat in Patients With Deletion 5q Lower-Risk Myelodysplastic Syndromes: Results From the IMerge Clinical Trial	14
Pharmacokinetic Assessment of Revumenib in Patients With Relapsed/Refractory Acute Leukemias Harboring a Lysine Methyltransferase 2A Rearrangement or Nucleophosmin 1 Mutation: Impact of Food and Concomitant Medications	15
Precision Monitoring: Standardizing Patient-Reported Signals to Improve Clinical Decision-Making Using Real-World Data	16
Durable Efficacy and Safety With Lovotibeglogene Autotemcel for Sickle Cell Disease	17
Subcutaneous Mosunetuzumab Plus Polatuzumab Vedotin Is Associated With Improvements in Health-Related Quality of Life Versus Rituximab-Gemcitabine-Oxaliplatin in Patients With Relapsed/Refractory Large B-Cell Lymphoma	18